argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of PipelineGlobeNewsWire • 03/06/26
Baron International Growth Fund Q4 2025: Contributors, Detractors, And TradesSeeking Alpha • 02/27/26
argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business UpdateGlobeNewsWire • 02/26/26
argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia GravisGlobeNewsWire • 02/26/26
argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMGGlobeNewsWire • 01/13/26
argenx SE (ARGX) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/12/26